Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 909-917

  Ochoa Gondar, Olga ^a   Vila Corcoles, Angel ^a   Rodriguez Blanco, Teresa ^b   Gomez Bertomeu, Frederic ^c   Figuerola Massana, Enric ^c   Raga Luria, Xavier ^d   Hospital Guardiola, Imma ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d Hospital Santa Tecla   (Spain)

Author keywords

Elderly; Pneumococcal vaccination; Pneumonia

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; VACCINATION; VERY ELDERLY; COMMUNITY-ACQUIRED INFECTIONS; INCIDENCE; MIDDLE AGED; MORTALITY; PNEUMONIA, PNEUMOCOCCAL;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SPAIN;

EID: 84901406293     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu002     Document Type: Article

References (31)

1. Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6.
2. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-8):1-24.
3. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2003: 529-88.
4. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: comparison of metaanalyses. Eur J Epidemiol 2004; 19:353-63.
5. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infections in adults (review). Cochrane Database Syst Rev 2013; 1: CD000422.
6. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58.
7. Vila-Corcoles A. Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia? Lancet Infect Dis 2008; 8:405-6.
8. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004.
9. Domínguez A, Izquierdo C, Salleras L, et al.; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36:608-14.
10. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012; 61:394-5.
11. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health 2010; 10:25.
12. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al.; EPIVAC Study Group. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health 2012; 12:222.
13. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, de Diego C, Satue E. Ineffectiveness of pneumococcal vaccination in cardiovascular prevention: the CAPAMIS study. JAMA Intern Med 2013; 173:1918-20.
14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GDDean CH. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-S72.
15. Gutierrez F, Masia M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOWassay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286-92.
16. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173:387-93.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81.
18. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149-1156.
19. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
20. Hosmer DW, Lemeshow S. Applied survival analysis. Regression modeling of time to event data. New York: John Wiley & Sons, 1999.
21. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-77.
22. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Metaanalysis. Can Fam Physician 1999; 45:2381-93.
23. Moore RA,Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1.
24. Cornu C, Yzebe D, Leophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-90.
25. Mantagni P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8.
26. Watson L,Wilson BJ,Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20:2166-73.
27. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22:3214-24.
28. Fedson DS, Lise C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22:927-46.
29. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, et al.; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8.
30. Nossal GJ. Vaccines of the future. Vaccine. 2011; 29(suppl 4):D111-5.
31. Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development. Curr Drug Targets 2012; 13:323-37.